Status:
COMPLETED
Nasonex® Nasal Suspension 50 μg Long-term Designated Drug Use Investigation (Study P05876)
Lead Sponsor:
Organon and Co
Conditions:
Allergic Rhinitis
Eligibility:
All Genders
Brief Summary
The investigation will be conducted to define safety and efficacy under the conditions of post-marketing use of this drug in subjects with allergic rhinitis. Post-marketing surveys are not considered...
Eligibility Criteria
Inclusion
- Patients who are treated with Nasonex for perennial or seasonal allergic rhinitis.
Exclusion
- Patients with an infection for which there is no effective antimicrobial drug or systemic fungal infection \[symptoms may exacerbate\]
- Patients with a history of hypersensitivity to any ingredient of this drug
Key Trial Info
Start Date :
November 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2012
Estimated Enrollment :
3806 Patients enrolled
Trial Details
Trial ID
NCT00903721
Start Date
November 1 2008
End Date
October 1 2012
Last Update
February 16 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.